VGLL1-TEAD4复合体在肿瘤中的研究进展

doi:10.3760/cma.j.cn371439-20250719-00028

摘要/Abstract

摘要：

VGLL1在多种侵袭性肿瘤中过表达，主要通过与TEAD4结合形成VGLL1-TEAD4复合体，调控下游靶基因参与肿瘤增殖、侵袭、转移及免疫逃逸等过程。探讨以该复合体结合界面为靶点的小分子抑制剂、肽类药物的治疗策略，分析靶向VGLL1-TEAD4复合体在胃癌、乳腺癌等实体瘤治疗中的临床转化潜力，可为肿瘤的机制研究和靶向治疗提供理论依据。

关键词: 肿瘤, 分子靶向治疗, VGLL1-TEAD4复合体

Abstract:

VGLL1 is overexpressed in various aggressive tumors. It primarily forms the VGLL1-TEAD4 complex by binding to TEAD4，which regulates downstream target genes to participate in processes such as tumor proliferation，invasion，metastasis，and immune evasion. This paper explores the therapeutic strategies of small-molecule inhibitors and peptide-based drugs targeting the binding interface of this complex，and analyzes the clinical translational potential of the targeted VGLL1-TEAD4 complex in the treatment of solid tumors such as gastric cancer and breast cancer，with the aim of providing a theoretical foundation for understanding oncogenic mechanisms and developing targeted therapies.

Key words: Neoplasms, Molecular targeted therapy, VGLL1-TEAD4 complex

史海燕, 马彦, 王若莹, 邵萨如拉, 郭瑞芳. VGLL1-TEAD4复合体在肿瘤中的研究进展[J]. 国际肿瘤学杂志, 2026, 53(3): 174-177.

Shi Haiyan, Ma Yan, Wang Ruoying, Shao Sarula, Guo Ruifang. Research progress of the VGLL1-TEAD4 complex in tumors[J]. Journal of International Oncology, 2026, 53(3): 174-177.

参考文献 26

[1]	Fu M, Hu Y, Lan T, et al. The Hippo signalling pathway and its implications in human health and diseases[J]. Signal Transduct Target Ther, 2022, 7(1): 376. DOI: 10.1038/s41392-022-01191-9.
[2]	Perry CH, Lavado A, Thulabandu V, et al. TEAD switches interacting partners along neural progenitor lineage progression to execute distinct functions[J]. Genes Dev, 2025, 39(13/14): 849-867. DOI: 10.1101/gad.352632.125.
[3]	Sonnemann HM, Pazdrak B, Antunes DA, et al. Vestigial-like 1(VGLL1): an ancient co-transcriptional activator linking wing, placenta, and tumor development[J]. Biochim Biophys Acta Rev Cancer, 2023, 1878(3): 188892. DOI: 10.1016/j.bbcan.2023.188892.
[4]	Sonnemann HM, Pazdrak B, Nassif B, et al. Placental co-transcriptional activator vestigial-like 1 (VGLL1) drives tumorigenesis via increasing transcription of proliferation and invasion genes[J]. Front Oncol, 2024, 14: 1403052. DOI: 10.3389/fonc.2024.1403052.
[5]	Yang Y, Jia W, Luo Z, et al. VGLL1 cooperates with TEAD4 to control human trophectoderm lineage specification[J]. Nat Commun, 2024, 15(1): 583. DOI: 10.1038/s41467-024-44780-8. pmid: 38233381
[6]	Kim BK, Cheong JH, Im JY, et al. PI3K/AKT/β-catenin signaling regulates vestigial-like 1 which predicts poor prognosis and enhances malignant phenotype in gastric cancer[J]. Cancers (Basel), 2019, 11(12): 1923. DOI: 10.3390/cancers11121923.
[7]	Im JY, Kim DM, Park H, et al. VGLL1 phosphorylation and activation promotes gastric cancer malignancy via TGF-β/ERK/RSK2 signaling[J]. Biochim Biophys Acta Mol Cell Res, 2021, 1868(1): 118892. DOI: 10.1016/j.bbamcr.2020.118892.
[8]	Hwang MA, Won M, Im JY, et al. TNF-α secreted from macrophages increases the expression of prometastatic integrin α_ν in gastric cancer[J]. Int J Mol Sci, 2022, 24(1): 376. DOI: 10.3390/ijms24010376.
[9]	Lei L, Yang J, Peng H, et al. The prognostic significance of the TEAD4 in hepatocellular carcinoma[J]. Int J Gen Med, 2023, 16: 6005-6013. DOI: 10.2147/IJGM.S440973. pmid: 38144438
[10]	Mesrouze Y, Chène P. Study of the TEAD-binding domain of the VGLL1, VGLL2 and VGLL3 proteins from vertebrates[J]. Arch Biochem Biophys, 2024, 760: 110136. DOI: 10.1016/j.abb.2024.110136.
[11]	Héberlé É, Bardet AF. Sensitivity of transcription factors to DNA methylation[J]. Essays Biochem, 2019, 63(6): 727-741. DOI: 10.1042/EBC20190033. pmid: 31755929
[12]	Fu K, Bonora G, Pellegrini M. Interactions between core histone marks and DNA methyltransferases predict DNA methylation patterns observed in human cells and tissues[J]. Epigenetics, 2020, 15(3): 272-282. DOI: 10.1080/15592294.2019.1666649. pmid: 31509087
[13]	Pobbati AV, Chan SW, Lee I, et al. Structural and functional similarity between the vgll1-TEAD and the YAP-TEAD complexes[J]. Structure, 2012, 20(7): 1135-1140. DOI: 10.1016/j.str.2012.04.004. pmid: 22632831
[14]	Chen Y, Jia K, Xie Y, et al. The current landscape of gastric cancer and gastroesophageal junction cancer diagnosis and treatment in China: a comprehensive nationwide cohort analysis[J]. J Hematol Oncol, 2025, 18(1): 42. DOI: 10.1186/s13045-025-01698-y.
[15]	Zhan L, Wu W, Yang Q, et al. Transcription factor TEAD4 facilitates glycolysis and proliferation of gastric cancer cells by activating PKMYT1[J]. Mol Cell Probes, 2023, 72: 101932. DOI: 10.1016/j.mcp.2023.101932.
[16]	Di Marco F, Cufaro MC, Damiani V, et al. Proteomic meta-analysis unveils new frontiers for biomarkers research in pancreatic carcinoma[J]. Oncogenesis, 2025, 14(1): 3. DOI: 10.1038/s41389-025-00547-4. pmid: 39956821
[17]	Drexler R, Fahy R, Küchler M, et al. Association of subcellular localization of TEAD transcription factors with outcome and progre-ssion in pancreatic ductal adenocarcinoma[J]. Pancreatology, 2021, 21(1): 170-179. DOI: 10.1016/j.pan.2020.12.003.
[18]	Kim S, Leem G, Choi J, et al. Integrative analysis of spatial and single-cell transcriptome data from human pancreatic cancer reveals an intermediate cancer cell population associated with poor prognosis[J]. Genome Med, 2024, 16(1): 20. DOI: 10.1186/s13073-024-01287-7. pmid: 38297291
[19]	Li H, Cai L, Pan Q, et al. N⁶-methyladenosine-modified VGLL1 promotes ovarian cancer metastasis through high-mobility group AT-hook 1/Wnt/β-catenin signaling[J]. iScience, 2024, 27(3): 109245. DOI: 10.1016/j.isci.2024.109245.
[20]	Tong X, Liu YS, Tong R, et al. TEAD4 predicts poor prognosis and transcriptionally targets PLAGL2 in serous ovarian cancer[J]. Hum Cell, 2023, 36(4): 1535-1547. DOI: 10.1007/s13577-023-00908-4. pmid: 37145265
[21]	Zhang S, Guo L, Tao R, et al. Ferroptosis-targeting drugs in breast cancer[J]. J Drug Target, 2025, 33(1): 42-59. DOI: 10.1080/1061186X.2024.2399181.
[22]	Parimita S, Das A, Samanta S. VGLL1 stabilization of cytoplasmic TAZ promotes EGFR expression and maintains tumor initiating cells in breast cancer independent of TEAD[J]. Cell Signal, 2024, 118: 111120. DOI: 10.1016/j.cellsig.2024.111120.
[23]	Hsu SC, Lin CY, Lin YY, et al. TEAD4 as an oncogene and a mitochondrial modulator[J]. Front Cell Dev Biol, 2022, 10: 890419. DOI: 10.3389/fcell.2022.890419.
[24]	He L, Yuan L, Sun Y, et al. Glucocorticoid receptor signaling activates TEAD4 to promote breast cancer progression[J]. Cancer Res, 2019, 79(17): 4399-4411. DOI: 10.1158/0008-5472.CAN-19-0012. pmid: 31289134
[25]	Ogimoto T, Ozasa H, Tsuji T, et al. Combination therapy with EGFR tyrosine kinase inhibitors and TEAD inhibitor increases tumor suppression effects in EGFR mutation-positive lung cancer[J]. Mol Cancer Ther, 2024, 23(4): 564-576. DOI: 10.1158/1535-7163.MCT-23-0371.
[26]	Hasegawa T, Sugihara T, Hoshino Y, et al. Photosensitizer verteporfin inhibits the growth of YAP- and TAZ-dominant gastric cancer cells by suppressing the anti-apoptotic protein survivin in a light-independent manner[J]. Oncol Lett, 2021, 22(4): 703. DOI: 10.3892/ol.2021.12964. pmid: 34457058